Cargando…

Pathophysiology of Portal Hypertension

The bases of our current knowledge on the physiology of the hepatic portal system are largely owed to the work of three pioneering vascular researchers from the sixteenth and the seventeenth centuries: A. Vesalius, W. Harvey, and F. Glisson. Vesalius is referred to as the founder of modern human ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morales-Ruiz, Manuel, Rodríguez-Vita, Juan, Ribera, Jordi, Jiménez, Wladimiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153457/ http://dx.doi.org/10.1007/978-3-642-37078-6_144

Ejemplares similares

Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats
por: Ribera, Jordi, et al.
Publicado: (2019)

Sipa1l1 is an early biomarker of liver fibrosis in CCl(4)-treated rats
por: Marfà, Santiago, et al.
Publicado: (2016)

Portal hypertension: pathophysiology and treatment

Pathophysiology of Portal Hypertension and Esophageal Varices
por: Maruyama, Hitoshi, et al.
Publicado: (2012)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics
por: Gunarathne, Lakmie S, et al.
Publicado: (2020)

Torsion of spleen and portal hypertension: Pathophysiology and clinical implications
por: Jha, Ashish Kumar, et al.
Publicado: (2021)

Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis
por: Segovia-Silvestre, Toni, et al.
Publicado: (2011)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Mechanobiology of portal hypertension
por: Felli, Eric, et al.
Publicado: (2023)

Cerium oxide nanoparticles improve liver regeneration after acetaminophen-induced liver injury and partial hepatectomy in rats
por: Córdoba-Jover, Bernat, et al.
Publicado: (2019)

Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure
por: Jagdish, Rakesh Kumar, et al.
Publicado: (2023)

Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes
por: Carvajal, Silvia, et al.
Publicado: (2019)

The loss of DHX15 impairs endothelial energy metabolism, lymphatic drainage and tumor metastasis in mice
por: Ribera, Jordi, et al.
Publicado: (2021)

Advances in therapeutic options for portal hypertension
por: Vilaseca, Marina, et al.
Publicado: (2018)

Portale Hypertension
por: Bauer, J., et al.
Publicado: (2011)

Emerging Therapeutic Targets for Portal Hypertension
por: Felli, Eric, et al.
Publicado: (2023)

Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease
por: Carvajal, Silvia, et al.
Publicado: (2019)

Portal Hypertension
por: Sun, Mingyu, et al.
Publicado: (2018)

Hematological Indices in Portal Hypertension: Cirrhosis versus Noncirrhotic Portal Hypertension
por: Sahin, Abdurrahman, et al.
Publicado: (2018)

Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension
por: Ortega-Ribera, Martí, et al.
Publicado: (2023)

The circulation in portal hypertension.
por: Witte, C. L., et al.
Publicado: (1975)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

Regression of portal hypertension: underlying mechanisms and therapeutic strategies
por: Selicean, Sonia, et al.
Publicado: (2021)

Sinistral portal hypertension
por: Thompson, Richard J, et al.
Publicado: (2006)

Biology of portal hypertension
por: McConnell, Matthew, et al.
Publicado: (2017)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
por: Hsu, Shao-Jung, et al.
Publicado: (2020)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte‐Mediated Paracrine Mechanism
por: Gracia‐Sancho, Jordi, et al.
Publicado: (2019)

Management of Portal Hypertension in Children
por: Mileti, Elizabeth, et al.
Publicado: (2010)

On Certain Aspects of Portal Hypertension
por: Learmonth, James
Publicado: (1951)

A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
por: Boyer-Diaz, Zoe, et al.
Publicado: (2019)

Erosive Gastritis and Portal Hypertension
por: Geraghty, J. G., et al.
Publicado: (1992)

The kidney in cirrhosis with portal hypertension
por: Olteanu, D, et al.
Publicado: (2010)

Clinical Manifestations of Portal Hypertension
por: Al-Busafi, Said A., et al.
Publicado: (2012)

Endoscopic Management of Portal Hypertension
por: Al-Busafi, Said A., et al.
Publicado: (2012)

Lack of a 5.9 kDa Peptide C-Terminal Fragment of Fibrinogen α Chain Precedes Fibrosis Progression in Patients with Liver Disease
por: Marfà, Santiago, et al.
Publicado: (2014)

Carvedilol in the Treatment of Portal Hypertension
por: Al-Ghamdi, Hamdan
Publicado: (2011)

Management of Complications of Portal Hypertension
por: Vilela, Eduardo Garcia, et al.
Publicado: (2019)

An Anomalous Cause of Portal Hypertension
por: Brown, Sara A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dphts44qsai7ns87fk6611tq8i